Patent Application
20190262355
The present invention relates to the combination of a BRD4 inhibitor with an antifolate (particularly an MTHFD1 inhibitor) for use in the treatment or prevention of cancer. The invention also relates to an antifolate (particularly an MTHFD1 inhibitor) for use in resensitizing a BRD4 inhibitor-resistant cancer to the treatment with a BRD4 inhibitor. The invention further provides a pharmaceutical composition comprising a BRD4 inhibitor, an antifolate (particularly an MTHFD1 inhibitor), and a pharmaceutically acceptable excipient. Moreover, the invention provides a method of assessing the susceptibility or responsiveness of a subject to the treatment with a BRD4 inhibitor, wherein the subject has been diagnosed as suffering from cancer or is suspected of suffering from cancer, the method comprising determining the level of nuclear folate and/or the level of expression of MTHFD1 in a sample obtained from the subject.
Chromatin controls gene expression in response to environmental signals. Key mediators of this process are cellular metabolites that act as cofactors and inhibitors of chromatin-modifying enzymes and are thought to enter the nucleus through uncontrolled influx from the cytoplasm.
Bromodomain-containing protein 4 (BRD4) is an important chromatin regulator, with described roles in gene activation, DNA damage, cell proliferation and cancer progression1-8. At least seven inhibitors of this bromodomain protein have reached the clinical stage and are currently evaluated for their efficacy in different cancers. The clinical benefit of BRD4 inhibitors is largely considered to be mediated by the direct repression of the driver oncogene c-MYC2,7. This notion is further supported by the recent discovery of the restoration of MYC expression and activation of WNT signaling as the major resistance mechanism to BRD4 inhibitors9,10.
Despite its clinical importance and the broad role of BRD4 in chromatin organization, surprisingly little is known about factors that are directly required for BRD4 function. The focus of most studies is the role of BRD4 as transcriptional activator, thought to be mediated by the binding of the tandem bromodomains to acetylated histone lysines, resulting in transcription factor recruitment and pTEFb mediated activation of paused RNA polymerase II. In addition, several proteins have been identified as direct BRD4 interactors, including viral protein LANA-111 and chromatin proteins NSD3, ATAD5, CHD4, LTSCR1, and JMJD512-14.
To identify if these or other proteins are directly required for BRD4 function, the inventors made use of a reporter cell line for monitoring the inhibition of BRD4. They recently established the REDS (reporter for epigenetic drug screening) cell line, confirmed the high selectivity of the reporter system for functional BRD4 inhibition and successfully pinpointed a crosstalk of BRD4 and TAF1 bromodomain inhibitors15. The haploid nature of the KBM7 cell line employed for the generation of REDSs makes it ideally suited for genetic screens for new BRD4 functional partners using a Gene-Trap (GT) approach. Here, remarkable results have been obtained with this strategy, leading to the identification of methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) as genetic and physical interactor of BRD4. The description of a nuclear role of this C-1-tetrahydrofolate synthase, as identified in the present invention, highlights a robust connection between cancer epigenetics and folate metabolism.
As detailed in the examples, the inventors found a direct transcriptional role of the folate-pathway enzyme MTHFD1, which they identified from a haploid genetic screen for factors required for BRD4 function. It has been shown that MTHFD1 can translocate into the nucleus and a fraction of it is chromatin-bound via direct physical interaction with BRD4, and occupies a subset of BRD4-bound loci in the genome. Moreover, it has been shown in multiple cell lines that the inhibition or downregulation of MTHFD1 induces similar transcriptional changes as inhibition or downregulation of BRD4. It has furthermore been demonstrated that the inhibition of either BRD4 or MTHFD1 results in similar changes in the nuclear metabolite composition. Moreover, it has been found that pharmacologic inhibitors of the two enzymes synergize, and that methotrexate can render (S)-JQ1 resistant cells sensitive. In addition, pharmacologic inhibitors of the two enzymes also synergize in vivo arresting tumor proliferation in a mouse xenograft model. Finally, the finding that the majority of biosynthetic enzymes required for nucleotide biosynthesis are in a tightly chromatin-bound fraction indicates a direct role of nuclear metabolism in the control of gene expression and enables new clinical strategies for BRD4 inhibitors in cancer.
Accordingly, the inventors have identified MTHFD1 as a functional genetic interactor of BRD4 and have shown that the loss of MTHFD1 phenocopies BRD4 inhibition. MTHFD1 is a key enzyme in folate metabolism, thereby providing important intermediates for the biosynthesis of nucleotides and methionine. MTHFD1 and BRD4 interact physically in the nucleus, and inhibition of either protein causes similar changes to nuclear metabolite composition. Inhibitors of the two enzymes have been found to synergize to impair the viability of multiple cancer cell lines.
Thus, in the context of the present invention, it has surprisingly been found that the use of a BRD4 inhibitor (such as, e.g., (S)-JQ1) in combination with an antifolate (particularly an MTHFD1 inhibitor; such as, e.g., methotrexate) provides a synergistically enhanced therapeutic effect against a range of different cancer cell lines, and hence allows an improved therapy of cancer. Moreover, it has been found that an antifolate (particularly an MTHFD1 inhibitor, such as methotrexate) can be used to resensitize BRD4 inhibitor-resistant cancer (such as (S)-JQ1-resistant cancer) to the treatment with a BRD4 inhibitor. The combined use of a BRD4 inhibitor together with an antifolate (or an MTHFD1 inhibitor) is furthermore advantageous as it allows to prevent or reduce the emergence of resistance to BRD4 inhibitors in cancer. The present invention thus solves the problem of providing an improved therapy for cancer, including in particular BRD4 inhibitor-resistant cancer,
Accordingly, the present invention provides a combination of a BRD4 inhibitor and an antifolate (particularly a combination of a BRD4 inhibitor and an MTHFD1 inhibitor) for use in therapy, preferably for use in treating or preventing cancer.
The invention also provides a BRD4 inhibitor for use in therapy, preferably for use in treating or preventing cancer, wherein the BRD4 inhibitor is to be administered in combination with an antifolate (particularly an MTHFD1 inhibitor).
The invention likewise relates to an antifolate (particularly an MTHFD1 inhibitor) for use in therapy, preferably for use in treating or preventing cancer, wherein the antifolate (or the MTHFD1 inhibitor) is to be administered in combination with a BRD4 inhibitor.
The invention further provides a pharmaceutical composition comprising a BRD4 inhibitor, an antifolate (particularly an MTHFD1 inhibitor), and a pharmaceutically acceptable excipient. The invention also relates to the aforementioned pharmaceutical composition for use in treating or preventing cancer.
Moreover, the present invention provides an antifolate (particularly an MTHFD1 inhibitor) for use in resensitizing a BRD4 inhibitor-resistant cancer to the treatment with a BRD4 inhibitor. The BRD4 inhibitor-resistant cancer may, in particular, be a cancer that is resistant to BRD4 inhibitor monotherapy.
The present invention furthermore relates to the use of a BRD4 inhibitor in combination with an antifolate (particularly an MTHFD1 inhibitor) for the preparation of a medicament for treating or preventing cancer. The invention likewise provides the use of a BRD4 inhibitor for the preparation of a medicament for treating or preventing cancer, wherein the BRD4 inhibitor is to be administered in combination with an antifolate (particularly an MTHFD1 inhibitor). The invention also relates to the use of an antifolate (particularly an MTHFD1 inhibitor) for the preparation of a medicament for treating or preventing cancer, wherein the antifolate (or the MTHFD1 inhibitor) is to be administered in combination with a BRD4 inhibitor. Moreover, the invention refers to the use of an antifolate (particularly an MTHFD1 inhibitor) for the preparation of a medicament for resensitizing a BRD4 inhibitor-resistant cancer (particularly a cancer that is resistant to BRD4 inhibitor monotherapy) to the treatment with a BRD4 inhibitor.
The present invention likewise relates to a method of treating or preventing a disease or disorder, preferably cancer, the method comprising administering a BRD4 inhibitor in combination with an antifolate (particularly an MTHFD1 inhibitor) to a subject (e.g., a human) in need thereof. The invention further provides a method of resensitizing a BRD4 inhibitor-resistant cancer to the treatment with a BRD4 inhibitor, the method comprising administering an antifolate (particularly an MTHFD1 inhibitor) to a subject (e.g., a human) in need thereof.
As described above, the present invention relates to the combination of a BRD4 inhibitor with an antifolate (particularly an MTHFD1 inhibitor) for use in therapy, preferably for use in treating or preventing cancer. The BRD4 inhibitor and the antifolate (or the BRD4 inhibitor and the MTHFD1 inhibitor) can be provided in separate pharmaceutical formulations. Such separate formulations can be administered either simultaneously or sequentially (e.g., the formulation comprising the BRD4 inhibitor may be administered first, followed by the administration of the formulation comprising the antifolate (or the MTHFD1 inhibitor), or vice versa). However, the BRD4 inhibitor and the antifolate (or the BRD4 inhibitor and the MTHFD1 inhibitor) can also be provided in a single pharmaceutical formulation. Accordingly, the invention also relates to a pharmaceutical composition comprising a BRD4 inhibitor, an antifolate (particularly an MTHFD1 inhibitor), and a pharmaceutically acceptable excipient. This novel pharmaceutical composition is useful, in particular, for the treatment or prevention of cancer.
The disease/disorder to be treated or prevented in accordance with the present invention is preferably a hyperproliferative disorder, and most preferably cancer. The cancer to be treated or prevented may, for example, be selected from gastrointestinal cancer, colorectal cancer, liver cancer (e,g., hepatocellular carcinoma), pancreatic cancer, stomach cancer, genitourinary cancer, bladder cancer, biliary tract cancer, testicular cancer, cervical cancer, malignant mesothelioma, esophageal cancer, laryngeal cancer, prostate cancer (e.g., hormone-refractory prostate cancer), lung cancer (e.g., small cell lung cancer or non-small cell lung cancer), breast cancer (e.g., triple-negative breast cancer, or breast cancer having a BRCA1 and/or BRCA2 gene mutation), hematological cancer, leukemia (e.g., acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, or chronic myeloid leukemia), lymphoma (e.g., Hodgkin lymphoma or non-Hodgkin lymphoma, such as, e.g., follicular lymphoma or diffuse large B-cell lymphoma), multiple myeloma, ovarian cancer, brain cancer, neuroblastoma, Ewing's sarcoma, osteogenic sarcoma, kidney cancer, epidermoid cancer, skin cancer, melanoma, head and/or neck cancer (e.g., head and neck squamous cell carcinoma), and mouth cancer. Preferably, the cancer to be treated or prevented is selected from prostate cancer, breast cancer, acute myeloid leukemia, acute lymphocytic leukemia, non-Hodgkin's lymphoma, multiple myeloma, bladder cancer, head and neck cancer, glioblastoma, mesothelioma, osteogenic sarcoma, choriocarcinoma, and NUT midline carcinoma. It is particularly preferred that the cancer to be treated or prevented (including any of the above-mentioned specific types of cancer) is a BRD4-dependent cancer and/or c-MYC-dependent cancer.
As described above, the present invention also relates to the treatment of BRD4 inhibitor-resistant cancer using the drug combination of the invention, i.e. a BRD4 inhibitor in combination with an antifolate (particularly an MTHFD1 inhibitor). The cancer to be treated (including any of the specific types of cancer referred to in the preceding paragraph) may thus also be a BRD4 inhibitor-resistant cancer, particularly a cancer that is resistant to BRD4 inhibitor monotherapy.
The BRD4 inhibitor to be used in accordance with the present invention is not particularly limited, and is preferably any one of (S)-JQ1, CeMMEC2, I-BET 151 (or GSK1210151A), I-BET 762 (or GSK525762), PF-1, bromosporine, OTX-015, TEN-010, CPI-203, CPI-0610, RVX-208, BI2536, TG101348, LY294002, or a pharmaceutically acceptable salt or solvate of any of these agents. These compounds are commercially available and/or their synthesis is described in the literature. For example, the compound CeMMEC2 can be obtained from AKos GmbH (Steinen, Germany). The BRD4 inhibitor may also be any one of the compounds disclosed in WO 2012/174487, WO 20141076146, US 2014/0135336, WO 2014/134583, WO 2014/191894, WO 2014/191896, US 2014/0349990, or WO 2014/191906. It is particularly preferred that the BRD4 inhibitor is (S)-JQ1 or CeMMEC2, and even more preferably it is (S)-JQ1.
Antifolates constitute an established class of pharmacological agents that antagonize or block the effects of folic acid on cellular processes. Antifolates like methotrexate and pemetrexed are approved agents used in cancer chemotherapy; they primarily target DHFR, but have also been shown to inhibit other enzymes in folate metabolism including MTHFD1. The antifolate to be used in accordance with the present invention is preferably an MTHFD1 inhibitor, i.e. an inhibitor of methylenetetrahydrofolate dehydrogenase 1 (MTHFD1). Examples of the antifolate include, in particular, methotrexate, pemetrexed, trimetrexate, edatrexate, lometrexol, 5-fluorouracil, pralatrexate, aminopterin, and pharmaceutically acceptable salts and solvates of these agents. A particularly preferred antifolate (or MTHFD1 inhibitor) in accordance with the invention is methotrexate or a pharmaceutically acceptable salt or solvate thereof (e.g., methotrexate sodium).
The scope of the invention embraces all pharmaceutically acceptable salt forms of the compounds to be used in accordance with the invention (also referred to as the compounds of the drug combination provided herein; including in particular the BRD4 inhibitors, the antifolates, and the MTHFD1 inhibitors referred to in this specification), which may be formed, e.g., by protonation of an atom carrying an electron lone pair which is susceptible to protonation, such as an amino group, with an inorganic or organic acid, or as a salt of an acid group (such as a carboxylic acid group) with a physiologically acceptable cation. Exemplary base addition salts comprise, for example: alkali metal salts such as sodium or potassium salts; alkaline earth metal salts such as calcium or magnesium salts; zinc salts; ammonium salts; aliphatic amine salts such as trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, procaine salts, meglumine salts, ethylenediamine salts, or choline salts; aralkyl amine salts such as N,N-dibenzylethylenediamine salts, benzathine salts, benethamine salts; heterocyclic aromatic amine salts such as pyridine salts, picoline salts, quinoline salts or isoquinoline salts; quaternary ammonium salts such as tetramethylammonium salts, tetraethylammonium salts, benzyltrimethylammonium salts, benzyltriethylammonium salts, benzyltributylammonium salts, methyltrioctylammonium salts or tetrabutylammonium salts; and basic amino acid salts such as arginine salts, lysine salts, or histidine salts. Exemplary acid addition salts comprise, for example: mineral acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate salts (such as, e.g., sulfate or hydrogensulfate salts), nitrate salts, phosphate salts (such as, e.g., phosphate, hydrogenphosphate, or dihydrogenphosphate salts), carbonate salts, hydrogencarbonate salts, perchlorate salts, borate salts, or thiocyanate salts; organic acid salts such as acetate, propionate, butyrate, pentanoate, hexanoate, heptanoate, octanoate, cyclopentanepropionate, decanoate, undecanoate, oleate, stearate, lactate, maleate, oxalate, fumarate, tartrate, malate, citrate, succinate, adipate, gluconate, glycolate, nicotinate, benzoate, salicylate, ascorbate, pamoate (embonate), camphorate, glucoheptanoate, or pivalate salts; sulfonate salts such as methanesulfonate (mesylate), ethanesulfonate (esylate), 2-hydroxyethanesulfonate (isethionate), benzenesuifonate (besylate), p-toluenesulfonate (tosylate), 2-naphthalenesulfonate (napsylate), 3-phenylsulfonate, or camphorsulfonate salts; glycerophosphate salts; and acidic amino acid salts such as aspartate or glutamate salts.
Moreover, the scope of the invention embraces the compounds to be used in accordance with the invention in any solvated form, including, e.g., solvates with water (i.e., as a hydrate) or solvates with organic solvents such as, e.g., methanol, ethanol or acetonitrile (i.e., as a methanolate, ethanolate or acetonitrilate), or in any crystalline form (i.e., as any polymorph), or in amorphous form. It is to be understood that such solvates of the compounds to be used in accordance with the invention also include solvates of pharmaceutically acceptable salts of the respective compounds.
Furthermore, the compounds to be used in accordance with the invention may exist in the form of different isomers, in particular stereoisomers (including, e.g., geometric isomers (or cis/trans isomers), enantiomers and diastereomers) or tautomers. All such isomers of the compounds referred to in this specification are contemplated as being part of the present invention, either in admixture or in pure or substantially pure form, As for stereoisomers, the invention embraces the isolated optical isomers of the compounds to be used according to the present invention as well as any mixtures thereof (including, in particular, racemic mixtures/racemates). The racemates can be resolved by physical methods, such as, e.g., fractional crystallization, separation or crystallization of diastereomeric derivatives, or separation by chiral column chromatography. The individual optical isomers can also be obtained from the racemates via salt formation with an optically active acid followed by crystallization. The present invention further encompasses any tautomers of the compounds provided herein.
The scope of the invention also embraces the compounds to be used in accordance with the invention, in which one or more atoms are replaced by a specific isotope of the corresponding atom. For example, the invention encompasses the use of the compounds referred to in this specification, in which one or more hydrogen atoms (or, e.g., all hydrogen atoms) are replaced by deuterium atoms (i.e., 2H; also referred to as “D”). Accordingly, the invention also embraces the compounds to be used in accordance with the invention which are enriched in deuterium. Naturally occurring hydrogen is an isotopic mixture comprising about 99.98 mol-% hydrogen-1 (1H) and about 0.0156 mol-% deuterium (2H or D). The content of deuterium in one or more hydrogen positions in the compounds to be used in accordance with the invention can be increased using deuteration techniques known in the art. For example, a compound referred to in the present specification or a reactant or precursor to be used in the synthesis of the corresponding compound can be subjected to an H/D exchange reaction using, e.g., heavy water (D2O). Further suitable deuteration techniques are described in: Atzrodt J et al., Bioorg Med Chem, 20(18), 5658-5667, 2012; William J S et al., Journal of Labelled Compounds and Radiopharmaceuticals, 53(11-12), 635-644, 2010; Modvig A et al., J Org Chem, 79, 5861-5868, 2014. The content of deuterium can be determined, e.g., using mass spectrometry or NMR spectroscopy, Unless specifically indicated otherwise, it is preferred that the compounds to be used in accordance with the invention are not enriched in deuterium. Accordingly, the presence of naturally occurring hydrogen atoms or 1H hydrogen atoms in the compounds to be used in accordance with the invention is preferred.
The invention furthermore provides a method (particularly an in vitro method) of assessing the susceptibility or responsiveness of a subject to the treatment with a BRD4 inhibitor, wherein the subject has been diagnosed as suffering from cancer or is suspected of suffering from cancer, the method comprising determining the level of nuclear folate and/or the level of expression of MTHFD1 in a sample obtained from the subject. It has been found that a smaller/lower level of nuclear folate and/or a smaller/lower expression level of MTHFD1, particularly a smaller/lower level of MTHFD1 protein in the nucleus of the corresponding cell, correlates with a greater susceptibility/responsiveness of the subject to the treatment with a BRD4 inhibitor. While the total expression level of MTHFD1 can also be predictive, the amount of MTHFD1 protein in the nucleus allows an even more accurate assessment of the susceptibility/responsiveness of the subject to the treatment with a BRD4 inhibitor. It is thus preferred that the level of expression of MTHFD1 is determined by determining the level of nuclear MTHFD1 protein, i.e., the amount of MTHFD1 protein in the nucleus of the corresponding cells.
The invention further provides a method (particularly an in vitro method) of assessing the susceptibility or responsiveness of a subject to the treatment with a BRD4 inhibitor, wherein the subject has been diagnosed as suffering from cancer or is suspected of suffering from cancer, the method comprising a step of determining the level of nuclear folate and/or the level of expression of MTHFD1 in a sample obtained from the subject, wherein a smaller level of nuclear folate and/or a smaller expression level of MTHFD1 in the sample from the subject is/are indicative of the subject being more susceptible or more responsive to the treatment with a BRD4 inhibitor. In this method, the level of nuclear folate (i.e., the level of folate in the nucleus of the corresponding cells), or the level of expression of MTHFD1, or both can be determined in order to assess the susceptibility or responsiveness of the subject to the treatment with a BRD4 inhibitor.
Accordingly, the invention also relates to a method (particularly an in vitro method) of assessing the susceptibility or responsiveness of a subject to the treatment with a BRD4 inhibitor, wherein the subject has been diagnosed as suffering from cancer or is suspected of suffering from cancer, the method comprising a step of determining the level of nuclear folate in a sample obtained from the subject, wherein a smaller level of nuclear folate in the sample from the subject is indicative of the subject being more susceptible or more responsive to the treatment with a BRD4 inhibitor.
The invention further relates to a method (particularly an in vitro method) of assessing the susceptibility or responsiveness of a subject to the treatment with a BRD4 inhibitor, wherein the subject has been diagnosed as suffering from cancer or is suspected of suffering from cancer, the method comprising a step of determining the level of expression of MTHFD1 in a sample obtained from the subject, wherein a smaller expression level of MTHFD1 in the sample from the subject is indicative of the subject being more susceptible or more responsive to the treatment with a BRD4 inhibitor. The level of expression of MTHFD1 is preferably determined by determining the level of nuclear MTHFD1 protein.
The description of exemplary or preferred features/embodiments provided herein with respect to the combination of a BRD4 inhibitor with an antifolate (or an MTHFD1 inhibitor), including inter alia the description of the cancer, the BRD4 inhibitor and the subject/patient, also applies to the above-described methods.
The sample to be used in the above-described methods is preferably a cancer tissue biopsy sample. Depending on the specific type of cancer, the sample may also be a body fluid, such as a blood sample (e.g., a whole blood sample, or a peripheral blood mononuclear cell fraction).
In some of the methods described above, the level of expression of MTHFD1 is determined in a sample obtained from the subject to be examined. The level of expression can be determined, for example, by determining the level of translation or the level of transcription of MTHFD1. Thus, the amount of MTHFD1 protein in the sample can be determined or the amount of MTHFD1 mRNA in the sample can be established in order to determine the level of expression of MTHFD1. This can be accomplished using methods known in the art, as described, e.g., in Green et al., 2012 (i.e., Green, M R et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Fourth Edition, 2012, ISBN: 978-1936113422). Preferably, the level of expression of MTHFD1 is determined by determining the level of translation of MTHFD1. More preferably, the level of expression of MTHFD1 is determined by determining the level of nuclear MTHFD1 protein, i.e. the amount of MTHFD1 protein specifically in the nucleus of the corresponding cells.
The level of translation of MTHFD1 can, e.g., be determined using antibody-based assays, such as an immunohistochemical method, an enzyme-linked immunosorbent assay (ELISA) or a radioimmunoassay (RIA), wherein antibodies directed specifically against the MTHFD1 protein to be quantified are employed, or mass spectrometry, a gel-based or blot-based assay, or flow cytometry (e.g., FACS). If the level of translation is to be determined, it may be advantageous to include one or more protease inhibitors in the sample from the subject.
The level of transcription of MTHFD1 can, e.g., be determined using a quantitative (real-time) reverse transcriptase polymerase chain reaction (“qRT-PCR”) or using a microarray (see, e.g., Ding C, et al. J Biochem Mol Biol. 2004; 37(1):1-10). It is also possible to use single-cell gene expression analysis techniques, such as single-cell qRT-PCR or single-cell microarray analysis, in order to determine the level of transcription of MTHFD1 in single cells from the sample. If the level of transcription is to be determined, it may further be advantageous to include one or more RNase inhibitors in the sample from the subject.
In accordance with the present invention, it is preferred that the level of expression of MTHFD1 is determined by determining the level of translation of MTHFD1, and particularly by determining the level of nuclear MTHFD1 protein. Preferably, the level of translation of MTHFD1 (or the level of nuclear MTHFD1 protein) is determined using an antibody-based assay, mass spectrometry, a gel-based or blot-based assay, or flow cytometry, more preferably using an immunohistochemical method, an enzyme-linked immunosorbent assay, or a radioimmunoassay, even more preferably using an immunohistochemical method. Methods for immunohistochemical staining are well-known in the art and are described, e.g., in: Renshaw, S., Immunohistochemistry: Methods Express, Scion Publishing Ltd, Bloxham (UK), 2007, ISBN: 9781904842033 (particularly chapter 4 “Immunochemical staining techniques”); Key, M., lmmunohistochemical staining methods: education guide, 2006 (particularly chapter 9); and Chen, X. et al. N Am J Med Sci 2(5), 241-245 (2010).
Thus, it is most preferred that the amount of nuclear MTHFD1 is determined. Immunofluorescence staining and immunohistochemistry are suitable methods for staining the protein with specific antibodies, and determination of the levels of the fluorescence signal in the nucleus (e.g., by co-staining with a DNA dye like DAPI, Hoechst 33258 or Hoechst 33342). Alternatively, nuclei can be isolated from tumor biopsies similarly to the isolation from cell lines described in
MTHFD1 is a C-1-tetrahydrofolate synthase that catalyzes three enzymatic reactions in folate metabolism, resulting in the interconversion of tetrahydrofolate (THF), 10-formyltetrahydrofolate (10-CHO-THF), 5,10-methenyltetrahydrofolate (5,10-CH=THF) and 5,10-methylenetetrahydrofolate (5,10-CH2-THF). It has been observed by the inventors that knock-down of either MTHFD1 or BRD4 resulted in lower levels of 5,10-CH2-THF. The nuclear levels of all folate metabolites can be determined following the isolation of nuclei, lysis, precipitation of proteins and analysis with methods including, e.g., HPLC-MS/MS and antibody-based methods like ELISA.
The present invention furthermore relates to a BRD4 inhibitor for use in the treatment of cancer in a subject, wherein the subject has been identified in any of the above-described methods as being susceptible or responsive to the treatment with a BRD4 inhibitor.
Moreover, the invention relates to the use of (i) a pair of primers for (i.e., binding to) a transcript of the gene MTHFD1, (ii) a nucleic acid probe to (i.e., binding to) a transcript of the gene MTHFD1, (iii) a microarray comprising a nucleic acid probe to (i.e., binding to) the transcript of the gene MTHFD1, or (iv) an antibody against (i.e., binding to) the protein MTHFD1, in a method (particularly an in vitro method) of assessing the susceptibility or responsiveness of a subject to the treatment with a BRD4 inhibitor, wherein the subject has been diagnosed as suffering from cancer or is suspected of suffering from cancer (e.g., any of the corresponding methods as described herein above).
The primers can be designed using methods known in the art (as also described, e.g., in Green et al., 2012) so as to allow the specific amplification/quantification of the transcript of the gene MTHFD1. Furthermore, the primers are preferably DNA primers.
The above-mentioned transcript is preferably an mRNA of the gene MTHFD1 or a cDNA synthesized from the mRNA of the gene MTHFD1. The nucleic acid probe comprises or consists of a nucleic acid capable of hybridizing with the transcript. The nucleic acid probe is preferably a single-stranded DNA probe or a single-stranded RNA probe, more preferably a single-stranded DNA probe. It is furthermore preferred that the nucleic acid probe (which may be, e.g., a single-stranded DNA or a single-stranded RNA, and is preferably a single-stranded DNA) is an oligonucleotide probe having, e.g., 10 to 80 nucleotides, preferably 15 to 60 nucleotides, more preferably 20 to 35 nucleotides, and even more preferably about 25 nucleotides. Such nucleic acid probes can be designed using methods known in the art (as also described, e.g., in Green et al., 2012) so as to allow the specific detection and quantification of the transcript of the corresponding gene.
The above-mentioned antibody against the protein MTHFD1 binds specifically to the protein MTHFD1 and may be, e.g., a polyclonal antibody or a monoclonal antibody. Preferably, the antibody is a monoclonal antibody. The antibody may further be a full/intact immunoglobulin molecule or a fragment/part thereof (such as, e.g., a separated light or heavy chain, an Fab fragment, an Fab/c fragment, an Fv fragment, an Fab′ fragment, or an F(ab′)2 fragment), provided that the fragment/part substantially retains the binding specificity of the corresponding full immunoglobulin molecule. The antibody may also be a modified and/or altered antibody, such as a chimeric or humanized antibody, a bifunctional or trifunctional antibody, or an antibody construct (such as a single-chain variable fragment (scFv) or an antibody-fusion protein). The antibody can be prepared using methods known in the art, as also described, e.g., in Harlow, E. et al., Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1998, ISBN: 978-0879695446. For example, monoclonal antibodies can be prepared by methods such as the hybridoma technique (see, e.g., Köhler G, et al. Nature. 1975; 256(5517):495-7), the trioma technique, the human B-cell hybridoma technique (see, e.g., Kozbor D, et al. Immunol Today. 1983; 4(3):72-9) or the EBV-hybridoma technique (see, e.g., Cole S P C, et al. Monoclonal Antibodies and Cancer Therapy. 1985; 27:77-96).
Thus, as described above, the present invention provides in particular:
(i) A BRD4 inhibitor for use in a method of treating cancer in a subject that has been diagnosed as suffering from cancer or is suspected of suffering from cancer, the method comprising:
(ii) A BRD4 inhibitor for use in a method of treating cancer in a subject that has been diagnosed as suffering from cancer or is suspected of suffering from cancer, the method comprising:
(iii) A BRD4 inhibitor for use in a method of treating cancer in a subject that has been diagnosed as suffering from cancer or is suspected of suffering from cancer, the method comprising:
(iv) A BRD4 inhibitor for use in a method of treating cancer in a subject that has been diagnosed as suffering from cancer or is suspected of suffering from cancer, the method comprising:
The compounds to be used in accordance with the invention may be administered as compounds per se or may be formulated as medicaments or pharmaceutical compositions. The medicaments/pharmaceutical compositions may optionally comprise one or more pharmaceutically acceptable excipients, such as carriers, diluents, fillers, disintegrants, lubricating agents, binders, colorants, pigments, stabilizers, preservatives, antioxidants, and/or solubility enhancers.
The pharmaceutical compositions may comprise one or more solubility enhancers, such as, e.g., poly(ethylene glycol), including poly(ethylene glycol) having a molecular weight in the range of about 200 to about 5,000 Da (e.g., PEG 200, PEG 300, PEG 400, or PEG 600), ethylene glycol, propylene glycol, glycerol, a non-ionic surfactant, tyloxapol, polysorbate 80, macrogol-15-hydroxystearate (e.g., Kolliphor® HS 15, CAS 70142-34-6), a phospholipid, lecithin, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, a cyclodextrin, α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, hydroxyethyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, hydroxyethyl-γ-cyclodextrin, hydroxypropyl-γ-cyclodextrin, dihydroxypropyl-β-cyclodextrin, sulfobutylether-β-cyclodextrin, sulfobutylether-γ-cyclodextrin, glucosyl-α-cyclodextrin, glucosyl-β-cyclodextrin, diglucosyl-β-cyclodextrin, maltosyl-α-cyclodextrin, maltosyl-β-cycfodextrin, maltosyl-γ-cyclodextrin, maltotriosyl-β-cyclodextrin, maltotriosyl-γ-cyclodextrin, dimaltosyl-β-cyclodextrin, methyl-β-cyclodextrin, a carboxyalkyl thioether, hydroxypropyl methylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, a vinyl acetate copolymer, vinyl pyrrolidone, sodium lauryl sulfate, dioctyl sodium sulfosuccinate, or any combination thereof.
The pharmaceutical compositions can be formulated by techniques known to the person skilled in the art, such as the techniques published in “Remington: The Science and Practice of Pharmacy”, Pharmaceutical Press, 22nd edition. The pharmaceutical compositions can be formulated as dosage forms for oral, parenteral, such as intramuscular, intravenous, subcutaneous, intradermal, intraarterial, intracardial, rectal, nasal, topical, aerosol or vaginal administration. Dosage forms for oral administration include coated and uncoated tablets, soft gelatin capsules, hard gelatin capsules, lozenges, troches, solutions, emulsions, suspensions, syrups, elixirs, powders and granules for reconstitution, dispersible powders and granules, medicated gums, chewing tablets and effervescent tablets. Dosage forms for parenteral administration include solutions, emulsions, suspensions, dispersions and powders and granules for reconstitution. Emulsions are a preferred dosage form for parenteral administration. Dosage forms for rectal and vaginal administration include suppositories and ovula. Dosage forms for nasal administration can be administered via inhalation and insufflation, for example by a metered inhaler. Dosage forms for topical administration include creams, gels, ointments, salves, patches and transdermal delivery systems.
The compounds to be used in accordance with the invention or the above described pharmaceutical compositions comprising such compounds may be administered to a subject by any convenient route of administration, whether systemically/peripherally or at the site of desired action, including but not limited to one or more of: oral (e.g., as a tablet, capsule, or as an ingestible solution), topical (e.g., transdermal, intranasal, ocular, buccal, and sublingual), parenteral (e.g., using injection techniques or infusion techniques, and including, for example, by injection, e.g., subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, or intrasternal by, e,g., implant of a depot, for example, subcutaneously or intramuscularly), pulmonary (e.g., by inhalation or insufflation therapy using, e.g., an aerosol, e.g., through mouth or nose), gastrointestinal, intrauterine, intraocular, subcutaneous, ophthalmic (including intravitreal or intracameral), rectal, or vaginal administration.
If said compounds or pharmaceutical compositions are administered parenterally, then examples of such administration include one or more of: intravenously, intraarterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracardially, intracranially, intramuscularly or subcutaneously administering the compounds or pharmaceutical compositions, and/or by using infusion techniques. For parenteral administration, the compounds are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
Said compounds or pharmaceutical compositions can also be administered orally in the form of tablets, capsules, ovules, elixirs, solutions or suspensions, which may contain flavoring or coloring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.
The tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycolate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included. Solid compositions of a similar type may also be employed as fillers in gelatin capsules. Preferred excipients in this regard include lactose, starch, a cellulose, or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the agent may be combined with various sweetening or flavoring agents, coloring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.
Alternatively, said compounds or pharmaceutical compositions can be administered in the form of a suppository or pessary, or may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder. The compounds of the present invention may also be dermally or transdermally administered, for example, by the use of a skin patch.
Said compounds or pharmaceutical compositions may also be administered by sustained release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include, e.g., polylactides (see, e.g., U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22:547-556 (1983)), poly(2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and R. Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al., Id.) or poly-D-(−)-3-hydroxybutyric acid (EP133988). Sustained-release pharmaceutical compositions also include liposomally entrapped compounds. Liposomes containing a compound of the present invention can be prepared by methods known in the art, such as, e.g., the methods described in any one of: DE3218121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci, (USA) 77:4030-4034 (1980); EP0052322; EP0036676; EP088046; EP0143949; EP0142641; JP 83-118008; U.S. Pat. No. 4,485,045; U.S. Pat. No. 4,544,545; and EP0102324.
Said compounds or pharmaceutical compositions may also be administered by the pulmonary route, rectal routes, or the ocular route. For ophthalmic use, they can be formulated as micronized suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.
It is also envisaged to prepare dry powder formulations of the compounds to be used in accordance with the invention for pulmonary administration, particularly inhalation. Such dry powders may be prepared by spray drying under conditions which result in a substantially amorphous glassy or a substantially crystalline bioactive powder. Accordingly, dry powders of the compounds to be used in the present invention can be made according to the emulsification/spray drying process disclosed in WO 99/16419 or WO 01/85136. Spray drying of solution formulations of the respective compounds can be carried out, e.g., as described generally in the “Spray Drying Handbook”, 5th ed., K. Masters, John Wiley & Sons, Inc., NY (1991), in WO 97/41833, or in WO 03/053411.
For topical application to the skin, said compounds or pharmaceutical compositions can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, emulsifying wax and water. Alternatively, they can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, 2-octyldodecanol, benzyl alcohol and water.
The present invention thus relates to the compounds or the pharmaceutical compositions provided herein, wherein the corresponding compounds or pharmaceutical compositions are to be administered by any one of: an oral route; topical route, including by transdermal, intranasal, ocular, buccal, or sublingual route; parenteral route using injection techniques or infusion techniques, including by subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, intrasternal, intraventricular, intraurethral, or intracranial route; pulmonary route, including by inhalation or insufflation therapy; gastrointestinal route; intrauterine route; intraocular route; subcutaneous route; ophthalmic route, including by intravitreal, or intracameral route; rectal route; or vaginal route. Particularly preferred routes of administration are oral administration or parenteral administration.
Typically, a physician will determine the actual dosage which will be most suitable for an individual subject. The specific dose level and frequency of dosage for any particular individual subject may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual subject undergoing therapy.
The combination of a BRD4 inhibitor with an antifolate (or with an MTHFD1 inhibitor) according to the present invention can also be used in combination with other therapeutic agents, including in particular other anticancer agents, for the treatment or prevention of cancer. When the above-mentioned drug combination according to the present invention is used in combination with a further therapeutic agent active against the same disease, the dose of each compound may differ from that when the compound is used alone. The combination of the drug combination of the present invention with a further therapeutic agent may comprise the administration of the further therapeutic agent simultaneously/concomitantly or sequentially/separately with the compounds of the drug combination according to the invention.
Preferably, the further therapeutic agent to be administered in combination with the compounds of the drug combination of the present invention is an anticancer drug. The anticancer drug may be selected from: a tumor angiogenesis inhibitor (e.g., a protease inhibitor, an epidermal growth factor receptor kinase inhibitor, or a vascular endothelial growth factor receptor kinase inhibitor); a cytotoxic drug (e.g., an antimetabolite, such as purine and pyrimidine analog antimetabolites); an antimitotic agent (e.g., a microtubule stabilizing drug or an antimitotic alkaloid); a platinum coordination complex; an anti-tumor antibiotic; an alkylating agent (e.g., a nitrogen mustard or a nitrosourea); an endocrine agent (e.g., an adrenocorticosteroid, an androgen, an anti-androgen, an estrogen, an anti-estrogen, an aromatase inhibitor, a gonadotropin-releasing hormone agonist, or a somatostatin analog); or a compound that targets an enzyme or receptor that is overexpressed and/or otherwise involved in a specific metabolic pathway that is misregulated in the tumor cell (e.g., ATP and GTP phosphodiesterase inhibitors, histone deacetylase inhibitors, protein kinase inhibitors (such as serine, threonine and tyrosine kinase inhibitors, e.g., Abelson protein tyrosine kinase inhibitors) and the various growth factors, their receptors and corresponding kinase inhibitors (such as epidermal growth factor receptor kinase inhibitors, vascular endothelial growth factor receptor kinase inhibitors, fibroblast growth factor inhibitors, insulin-like growth factor receptor inhibitors and platelet-derived growth factor receptor kinase inhibitors)); methionine, aminopeptidase inhibitors, proteasome inhibitors, cyclooxygenase inhibitors (e.g., cyclooxygenase-1 or cyclooxygenase-2 inhibitors), topoisomerase inhibitors (e.g., topoisomerase I inhibitors or topoisomerase II inhibitors), poly ADP ribose polymerase inhibitors (PARP inhibitors), and epidermal growth factor receptor (EGFR) inhibitors/antagonists.
An alkylating agent which can be used as an anticancer drug in combination with the compounds of the drug combination of the present invention may be, for example, a nitrogen mustard (such as cyclophosphamide, mechlorethamine (chlormethine), uramustine, melphalan, chlorambucil, ifosfamide, bendamustine, or trofosfamide), a nitrosourea (such as carmustine, streptozocin, fotemustine, lomustine, nimustine, prednimustine, ranimustine, or semustine), an alkyl sulfonate (such as busulfan, mannosulfan, or treosulfan), an aziridine (such as hexamethylmelamine (altretamine), triethylenemelamine, ThioTEPA (N,N′N′-triethylenethiophosphoramide), carboquone, or triaziquone), a hydrazine (such as procarbazine), a triazene (such as dacarbazine), or an imidazotetrazine (such as temozolomide).
A platinum coordination complex which can be used as an anticancer drug in combination with the compounds of the drug combination of the present invention may be, for example, cisplatin, carboplatin, nedaplatin, oxaliplatin, satraplatin, or triplatin tetranitrate.
A cytotoxic drug which can be used as an anticancer drug in combination with the compounds of the drug combination of the present invention may be, for example, an antimetabolite, including folic acid analogue antimetabolites (such as aminopterin, methotrexate, pemetrexed, or raltitrexed), purine analogue antimetabolites (such as cladribine, clofarabine, fludarabine, 6-mercaptopurine (including its prodrug form azathioprine), pentostatin, or 6-thioguanine), and pyrimidine analogue antimetabolites (such as cytarabine, decitabine, 5-fluorouracil (including its prodrug forms capecitabine and tegafur), floxuridine, gemcitabine, enocitabine, or sapacitabine).
An antimitotic agent which can be used as an anticancer drug in combination with the compounds of the drug combination of the present invention may be, for example, a taxane (such as docetaxel, larotaxel, ortataxel, paclitaxel/taxol, or tesetaxel), a Vinca alkaloid (such as vinblastine, vincristine, vinflunine, vindesine, or vinorelbine), an epothilone (such as epothilone A, epothilone B, epothilone C, epothilone D, epothilone E, or epothilone F) or an epothilone B analogue (such as ixabepilone/azaepothilone B).
An anti-tumor antibiotic which can be used as an anticancer drug in combination with the compounds of the drug combination of the present invention may be, for example, an anthracycline (such as aclarubicin, daunorubicin, doxorubicin, epirubicin, idarubicin, amrubicin, pirarubicin, valrubicin, or zorubicin), an anthracenedione (such as mitoxantrone, or pixantrone) or an anti-tumor antibiotic isolated from Streptomyces (such as actinomycin (including actinomycin D), bleomycin, mitomycin (including mitomycin C), or plicamycin),
A tyrosine kinase inhibitor which can be used as an anticancer drug in combination with the compounds of the drug combination of the present invention may be, for example, axitinib, bosutinib, cediranib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, lestaurtinib, nilotinib, semaxanib, sorafenib, sunitinib, or vandetanib.
A topoisomerase-inhibitor which can be used as an anticancer drug in combination with the compounds of the drug combination of the present invention may be, for example, a topoisomerase I inhibitor (such as irinotecan, topotecan, camptothecin, belotecan, rubitecan, or lamellarin D) or a topoisomerase II inhibitor (such as amsacrine, etoposide, etoposide phosphate, teniposide, or doxorubicin).
A PARP inhibitor which can be used as an anticancer drug in combination with the compounds of the drug combination of the present invention may be, for example, BMN-673, olaparib, rucaparib, veliparib, CEP 9722, MK 4827, BGB-290, or 3-aminobenzamide.
An EGFR inhibitor/antagonist which can be used as an anticancer drug in combination with the compounds of the drug combination of the present invention may be, for example, gefitinib, erlotinib, lapatinib, afatinib, neratinib, ABT-414, dacomitinib, AV-412, PD 153035, vandetanib, PKI-166, pelitinib, canertinib, icotinib, poziotinib, BMS-690514, CUDC-101, AP26113, XL647, cetuximab, panitumumab, zalutumumab, nimotuzumab, or matuzumab.
Further anticancer drugs may also be used in combination with the compounds of the drug combination of the present invention. The anticancer drugs may comprise biological or chemical molecules, like TNF-related apoptosis-inducing ligand (TRAIL), tamoxifen, amsacrine, bexarotene, estramustine, irofulven, trabectedin, cetuximab, panitumumab, tositumomab, alemtuzumab, bevacizumab, edrecolomab, gemtuzumab, alvocidib, seliciclib, aminolevulinic acid, methyl aminolevulinate, efaproxiral, porfimer sodium, talaporfin, temoporfin, verteporfin, alitretinoin, tretinoin, anagrelide, arsenic trioxide, atrasentan, bortezomib, carmofur, celecoxib, demecolcine, elesclomol, elsamitrucin, etoglucid, lonidamine, lucanthone, masoprocol, mitobronitol, mitoguazone, mitotane, oblimersen, omacetaxine, sitimagene, ceradenovec, tegafur, testolactone, tiazofurine, tipifarnib, vorinostat, or iniparib.
Also biological drugs, like antibodies, antibody fragments, antibody constructs (for example, single-chain constructs), and/or modified antibodies (like CDR-grafted antibodies, humanized antibodies, “full humanized” antibodies, etc.) directed against cancer or tumor markers/factors/cytokines involved in proliferative diseases can be employed in co-therapy approaches with the compounds of the drug combination of the present invention. Examples of such biological molecules are anti-HER2 antibodies (e.g. trastuzumab, Herceptin®), anti-CD20 antibodies (e.g. Rituximab, Rituxan®, MabThera®, Reditux®), anti-CD19/CD3 constructs (see, e.g., EP1071752) and anti-TNF antibodies (see, e.g., Taylor P C. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol. 2003. 3(3):323-328). Further antibodies, antibody fragments, antibody constructs and/or modified antibodies to be used in co-therapy approaches with the compounds of the drug combination of the invention can be found, e.g., in: Taylor P C. Curr Opin Pharmacol, 2003. 3(3):323-328; or Roxana A. Maedica. 2006. 1(1):63-65.
An anticancer drug which can be used in combination with the compounds of the drug combination of the present invention may, in particular, be an immunooncology therapeutic (such as an antibody (e.g., a monoclonal antibody or a polyclonal antibody), an antibody fragment, an antibody construct (e.g., a single-chain construct), or a modified antibody (e.g., a CDR-grafted antibody, a humanized antibody, or a “full humanized” antibody) targeting any one of CTLA-4, PD-1/PD-L1, TIM3, LAG3, OX4, CSF1R, IDO, or CD40. Such immunooncology therapeutics include, e.g., an anti-CTLA-4 antibody (particularly an antagonistic or pathway-blocking anti-CTLA-4 antibody; e.g., ipilimumab or tremelimumab), an anti-PD-1 antibody (particularly an antagonistic or pathway-blocking anti-PD-1 antibody; e.g., nivolumab (BMS-936558), pembrolizumab (MK-3475), pidilizumab (CT-011), AMP-224, or APE02058), an anti-PD-L1 antibody (particularly a pathway-blocking anti-PD-L1 antibody; e.g., BMS-936559, MEDI4736, MPDL3280A (RG7446), MDX-1105, or MEDI6469), an anti-TIM3 antibody (particularly a pathway-blocking anti-TIM3 antibody), an anti-LAG3 antibody (particularly an antagonistic or pathway-blocking anti-LAG3 antibody; e.g., BMS-986016, IMP701, or IMP731), an anti-OX4 antibody (particularly an agonistic anti-OX4 antibody; e.g., MEDI0562), an anti-CSF1R antibody (particularly a pathway-blocking anti-CSF1R antibody; e.g., IMC-CS4 or RG7155), an anti-IDO antibody (particularly a pathway-blocking anti-IDO antibody), or an anti-CD40 antibody (particularly an agonistic anti-CD40 antibody; e.g., CP-870,893 or Chi Lob 7/4). Further immunooncology therapeutics are known in the art and are described, e.g., in: Kyi C et al., FEBS Lett, 2014, 588(2):368-76; Intlekofer A M et al., J Leukoc Biol, 2013, 94(1):25-39; Callahan M K et al., J Leukoc Biol, 2013, 94(1):41-53; Ngiow S F et al., Cancer Res, 2011, 71(21):6567-71; and Blattman J N et al., Science, 2004, 305(5681):200-5.
The combinations with further anticancer drugs referred to above may conveniently be presented for use in the form of a pharmaceutical formulation. The individual components of such combinations may be administered either sequentially or simultaneously/concomitantly in separate or combined pharmaceutical formulations by any convenient route. When administration is sequential, either the compounds of the drug combination of the present invention or the further therapeutic agent may be administered first. When administration is simultaneous, the combination may be administered either in the same pharmaceutical composition or in different pharmaceutical compositions. When combined in the same formulation, it will be appreciated that the different compounds must be stable and compatible with each other and the other components of the formulation. When formulated separately, they may be provided in any convenient formulation.
The compounds of the drug combination of the present invention can also be administered in combination with physical therapy, such as radiotherapy. Radiotherapy may commence before, after, or simultaneously with administration of the compounds of the drug combination of the present invention. For example, radiotherapy may commence 1-10 minutes, 1-10 hours or 24-72 hours after administration of the corresponding compounds. Yet, these time frames are not to be construed as limiting. The subject is exposed to radiation, preferably gamma radiation, whereby the radiation may be provided in a single dose or in multiple doses that are administered over several hours, days and/or weeks. Gamma radiation may be delivered according to standard radiotherapeutic protocols using standard dosages and regimens.
The present invention thus relates to a combination of a BRD4 inhibitor with an antifolate (or with an MTHFD1 inhibitor), as described herein above, for use in treating or preventing cancer, wherein the compounds of this drug combination (i.e., the BRD4 inhibitor and the antifolate or the MTHFD1 inhibitor, or a pharmaceutical composition comprising these agents) are to be administered in combination with a further anticancer drug and/or in combination with radiotherapy.
The subject or patient to be treated in accordance with the present invention may be an animal (e.g., a non-human animal), a vertebrate animal, a mammal, a rodent (e.g., a guinea pig, a hamster, a rat, or a mouse), a canine (e.g., a dog), a feline (e.g., a cat), a porcine (e.g., a pig), an equine (e.g., a horse), a primate or a simian (e.g., a monkey or an ape, such as a marmoset, a baboon, a gorilla, a chimpanzee, an orangutan, or a gibbon), or a human. In accordance with the present invention, it is envisaged that animals are to be treated which are economically, agronomically or scientifically important. Scientifically important organisms include, but are not limited to, mice, rats, and rabbits, Lower organisms such as, e.g., fruit flies like Drosophila melagonaster and nematodes like Caenorhabditis elegans may also be used in scientific approaches. Non-limiting examples of agronomically important animals are sheep, cattle and pigs, while, for example, cats and dogs may be considered as economically important animals. Preferably, the subject/patient is a mammal. More preferably, the subject/patient is a human or a non-human mammal (such as, e.g., a guinea pig, a hamster, a rat, a mouse, a rabbit, a dog, a cat, a horse, a monkey, an ape, a marmoset, a baboon, a gorilla, a chimpanzee, an orangutan, a gibbon, a sheep, cattle, or a pig). Most preferably, the subject/patient is a human.
The term “treatment” of a disorder or disease as used herein (e.g., “treatment” of cancer) is well known in the art. “Treatment” of a disorder or disease implies that a disorder or disease is suspected or has been diagnosed in a patient/subject. A patient/subject suspected of suffering from a disorder or disease typically shows specific clinical and/or pathological symptoms which a skilled person can easily attribute to a specific pathological condition (i.e., diagnose a disorder or disease).
The “treatment” of a disorder or disease may, for example, lead to a halt in the progression of the disorder or disease (e.g., no deterioration of symptoms) or a delay in the progression of the disorder or disease (in case the halt in progression is of a transient nature only). The “treatment” of a disorder or disease may also lead to a partial response (e.g., amelioration of symptoms) or complete response (e.g., disappearance of symptoms) of the subject/patient suffering from the disorder or disease. Accordingly, the “treatment” of a disorder or disease may also refer to an amelioration of the disorder or disease, which may, e.g., lead to a halt in the progression of the disorder or disease or a delay in the progression of the disorder or disease. Such a partial or complete response may be followed by a relapse. It is to be understood that a subject/patient may experience a broad range of responses to a treatment (such as the exemplary responses as described herein above). The treatment of a disorder or disease may, inter aha, comprise curative treatment (preferably leading to a complete response and eventually to healing of the disorder or disease) and palliative treatment (including symptomatic relief).
The term “prevention” of a disorder or disease as used herein (e.g., “prevention” of cancer) is also well known in the art. For example, a patient/subject suspected of being prone to suffer from a disorder or disease may particularly benefit from a prevention of the disorder or disease. The subject/patient may have a susceptibility or predisposition for a disorder or disease, including but not limited to hereditary predisposition. Such a predisposition can be determined by standard methods or assays, using, e.g., genetic markers or phenotypic indicators. It is to be understood that a disorder or disease to be prevented in accordance with the present invention has not been diagnosed or cannot be diagnosed in the patient/subject (for example, the patient/subject does not show any clinical or pathological symptoms). Thus, the term “prevention” comprises the use of a compound of the present invention before any clinical and/or pathological symptoms are diagnosed or determined or can be diagnosed or determined by the attending physician.
As used herein, unless explicitly indicated otherwise or contradicted by context, the terms “a”, “an” and “the” are used interchangeably with “one or more” and “at least one”. Thus, for example, a composition comprising “a” BRD4 inhibitor can be interpreted as referring to a composition comprising “one or more” BRD4 inhibitors.
As used herein, the term “about” preferably refers to ±10% of the indicated numerical value, more preferably to ±5% of the indicated numerical value, and in particular to the exact numerical value indicated. For example, the expression “about 100” preferably refers to 100±10%, more preferably to 100±5%, and even more preferably to the specific value of 100.
As used herein, the term “comprising” (or “comprise”, “comprises”, “contain”, “contains”, or “containing”), unless explicitly indicated otherwise or contradicted by context, has the meaning of “containing, inter alia”, i.e., “containing, among further optional elements, . . . ”. In addition thereto, this term also includes the narrower meanings of “consisting essentially of” and “consisting of”. For example, the term “A comprising B and C” has the meaning of “A containing, inter alia, B and C”, wherein A may contain further optional elements (e.g., “A containing B, C and D” would also be encompassed), but this term also includes the meaning of “A consisting essentially of B and C” and the meaning of “A consisting of B and C” (i.e, no other components than B and C are comprised in A).
As used herein, the terms “optional”, “optionally” and “may” denote that the indicated feature may be present but can also be absent. Whenever the term “optional”, “optionally” or “may” is used, the present invention specifically relates to both possibilities, i.e., that the corresponding feature is present or, alternatively, that the corresponding feature is absent. For example, if a component of a composition is indicated to be “optional”, the invention specifically relates to both possibilities, i.e., that the corresponding component is present (contained in the composition) or that the corresponding component is absent from the composition.
It is to be understood that the present invention specifically relates to each and every combination of features and embodiments described herein, including any combination of general and/or preferred features/embodiments.
In this specification, a number of documents including patent documents and scientific literature are cited. The disclosure of these documents, while not considered relevant for the patentability of this invention, is herewith incorporated by reference in its entirety. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.
The reference in this specification to any prior publication (or information derived therefrom) is not and should not be taken as an acknowledgment or admission or any form of suggestion that the corresponding prior publication (or the information derived therefrom) forms part of the common general knowledge in the technical field to which the present specification relates.
The invention is also described by the following illustrative figures. The appended figures show:
The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention.
Methods:
Cell Culture and Transfection
KBM7 (human chronic myelogenous leukemia cell lines), MV4-11 (biphenotypic B myelomonocytic leukemia), MEG-01 (human chronic myelogenous leukemia), K-562 (human chronic myelogenous leukemia) and HAP1 (KBM7-derived) cell lines were cultured in Iscove's Modified Dulbecco's Medium (IMDM, Gibco), supplemented with 10% Fetal Bovine Serum (FBS; Gibco). HEK293T (human embryonic kidney) and HELA (cervix adenocarcinoma) cell lines were cultured in Dulbecco's Modified Eagles Medium (DMEM, Gibco) supplemented with 10% FBS. MOLM-13 (human acute monocytic leukemia), NOMO-1 (human acute monocytic leukemia) and A549 (lung carcinoma) cell lines were cultured in RPMI-1640 (Roswell Park Memorial Institute, Gibco) supplemented with 10% FBS. All the mentioned cell lines were incubated in 5% CO2 atmosphere at 37° C.
HEK293T cells were transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
The Retroviral gene trap vector (pGT-GFP; see below) was a gift from Dr. Sebastian Nijman, Group Leader at the Cell biology, Signaling, Therapeutics Program, Ludwig Cancer Research (Oxford, UK).
GFP-MTHFD1 plasmid was a gift from Professor Patrick Stover, Director of the Division of Nutritional Sciences, Cornell University (Ithaca, N.Y.).
Western Blot and Immunoprecipitation
For Western Blot, proteins were separated on polyacrylamide gels with SDS running buffer (50 mM Tris, 380 mM Glycine, 7 mM SDS) and transferred to nitrocellulose blotting membranes. All membranes were blocked with blocking buffer (5% (m/v) milk powder (BioRad) in TBST (Tris-Buffered Saline with Tween: 50 mM Tris (tris (hydroxymethyl)aminomethane), 150 mM NaCl, 0.05% (v/v) Tween 20, adjusted to pH 7.6). Proteins were probed with antibodies against BRD4 (ab128874, 1:1000, Abcam), Actin (ab16039, 1:1000, Abcam), MTHFD1 (ab70203, Abcam; H120, Santa Cruz; A8, Santa Cruz; all used at 1:1000), GFP (G10362, 1:1000, Life Technology), RCC1 (C-20, 1:1000, Santa Cruz), β-Tubulin (T-4026, 1:1000, Sigma), SHMT1 (ab186130, 1:1000, Abcam) and H2B (ab156197, 1:1000, Abcam) and detected by HRP (horseradish peroxidase) conjugated donkey anti-rabbit IgG antibody (ab16284, 1:5000, Abcam) or donkey anti-mouse IgG antibody (Pierce) and visualized with the Pierce ECL Western Blotting substrate (Amersham), according to the provided protocol.
For immunoprecipitation, 1 mg of protein extract was incubated overnight at 4° C. with 10 μl of Dynabeads (either A or G, Life technology) preincubated for 2 hours at 4° C. with 1 μg of BRD4 (ab128874, Abcam), MTHFD1 (A8, Santa Cruz) or GFP (G10362, Life Technology) antibodies.
Immunofluorescence and Live Cell Imaging
For immunofluorescence, cells were grown on coverslips precoated with Polylysine (Sigma). After the desired treatment, cells were washed with PBS and fixed with cold methanol for at least 24 hours. Blocking was performed in PBS/3% bovine serum albumin (BSA)/0.1% Triton for 30 minutes. Cells were then incubated with primary antibody for 30 minutes at room temperature (MTHFD1 H120, Santa Cruz; BRD4 ab128874, Abcam). After washing, they were incubated with secondary antibodies (Alexa Fluor 488 Goat Anti-Rabbit and Alexa Fluor 546 Donkey Anti-Mouse, Thermo Fisher Scientific) for 30 minutes in the dark. Finally, they were washed and incubated with DAPI (4,6-diamidino-2-phenylindole) for 5 minutes at room temperature in the dark. 3 PBS washing steps were done to remove the excess of antibodies and DAPI and coverslips were mounted with Propyl gallate (Sigma) on slides. Pictures were taken with a Leica DMI6000B inverted microscope and 63× oil objective and analyzed with Fiji (ImageJ).
Live cell imaging pictures were taken from cells seeded on clear flat bottom 96-well or 384-well plates (Corning), with the Operetta High Content Screening System (PerkinElmer), 20× objective and non-confocal mode. RFP quantification was done using the basic PerkinElmer software for nuclei detection and analysis, adapted for the nucleus diameter range of the specific cell line used (KBM7, 13 μm). Only RFP positive nuclei were detected and counted.
Cell Cycle Assay
For cell cycle analysis, 1 million cells were fixed with 70% ethanol for 24 hours, washed with PBS/1% BSA/0.1% Tween and incubated with RNase for 30 minutes. Nuclei were stained with 5 μg/ml PI (propidium iodide, Sigma) for 10 minutes prior to FACS analysis (BD FACSCalibur Flow Cytometer).
RNA Extraction and RT-PCR
RNA extraction was performed with TRIzol Reagent (Life Technologies) according to the standard protocol and Reverse Transcription (RT) was performed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
QPCR was performed using the Power SYBR Green Master mix (Invitrogen) as described in the manufacture's protocol.
QPCR primers used:
Real-time amplification results were normalized to the endogenous housekeeping gene Actin. The relative quantities were calculated using the comparative CT (Cycle Threshold) Method (ΔΔCT Method).
Gene-Trap Genetic Screening
pGT-GFP contains an inactivated 3′ LTR, a strong adenoviral (Ad40) splice-acceptor site, GFP and the SV40 polyadenylation signal. Gene trap virus was produced by transfection of 293T cells in T150 dishes with pGT-GFP combined with retroviral packaging plasmids. The virus-containing supernatant was collected after 30, 48 and 72 hours of transfection and concentrated using ultracentrifugation for 1.5 hours at 24100 rpm in a Beckman Coulter Optima L-100 XP ultracentrifuge using an SW 32 Ti rotor.
REDS1 clone was mutagenized by infection of 24-well tissue culture dish containing 1 million cells per well using spin infection for 45 minutes at 2000 rpm. GT-infected cells were assessed by FACS to determine the percentage of infection (percentage of GFP positive cells). If such percentage was above 70%, REDS1 GFP/RFP double positive cells were sorted and left in culture for 2 weeks to get the proper amount of cells to use in the library preparation for sequencing.
Cell Sorting
RFP/GFP double positive cell sorting was performed using the FACSAria (BD Biosciences) sorter. Gates for positive or negative RFP or GFP populations were done using the appropriate positive or negative controls, RFP/GFP double positive cells were sorted 7 days after GT infection. RFP/GFP double positive cells were grown up to get the needed amount for DNA library preparation (30 millions).
DNA Library Preparation
DNA was extracted from 30 million GFP/RFP double positive REDS1 cells using the Genomic DNA isolation QIAamp DNA mini kit (Qiagen). 4 μg were digested with NlaIII or MseI (4 digestions each enzyme). After spin column purification (Qiagen), 1 μg of digested DNA was ligated using T4 DNA ligase (NEB) in a volume of 300 μl (total of 4 ligations). The reaction mix was purified and retroviral insertion sites were identified via an inverse PCR protocol adapted to next generation sequencing16.
FISH Assay
The RFP specific probe (RFP_probe) was PCR performed using RFP specific primers (Sigma; forward 5′-CGGTTAAAGGTGCCGTCTCG, reverse 5′-AGGCTTCCCAGGTCACGATG) and labeled using dig-dUTP (DIG Nick Translation Mix, Roche). The FISH assay procedure was performed as previously described15.
AlphaLISA Assay
The Amplified Luminescent Proximity Homogenous Assay (AlphaLISA©), a homogenous and chemiluminescence-based method, was performed to explore the direct interaction of BRD4 and acetylated substrates.
Briefly, in this assay, the biotinylated MTHFD1 acetylated peptides (possible substrates) are captured by streptavidin-coupled donor beads. GST-tagged BRD4 (produced as previously described15) is recognized and bound by an anti-GST antibody conjugated with an acceptor bead. In case of interaction between BRD4 and one acetylated peptide, the proximity between the partners (<200 nm) allows that the excitation (680 nm wavelength) of a donor bead induces the release of a singlet oxygen molecule (1O2) that then triggers a cascade of energy transfer in the acceptor bead, resulting in a sharp peak of light emission at 615 nm.
GST-BRD4 and each of the MTHFD1 acetylated peptides were incubated together. After 30 minutes, GSH (Glutathione) Acceptor beads (PerkinElmer) were added and after another incubation time of 30 minutes, Streptavidin-conjugated donor beads (PerkinElmer) were added. The signal (alpha counts) was read by the EnVision 2104 Multilabel Reader (PerkinElmer).
Preparation of Nuclear Cell Extracts for Proteomics
Nuclear extract was produced from fresh cells grown at 5.0×10e6 cells/mL. Cells were collected by centrifugation, washed with PBS and resuspended in hypotonic buffer A (10 mM Tris-Cl, pH 7.4, 1.5 mM MgCl2, 10 mM KCl, 25 mM NaF, 1 mM Na3VO4, 1 mM DTT, and 1 Roche protease inhibitor tablet per 25 ml). After ca. 3 min cells were spun down and resuspended in buffer A and homogenized using a Dounce homogenizer. Nuclei were collected by centrifugation in a microfuge for 10 min at 3300 rpm, washed with buffer A and homogenized in one volume of extraction buffer B (50 mM Tris-Cl, pH 7.4, 1.5 mM MgCl2, 20% glycerol, 420 mM NaCl, 25 mM NaF, 1 mM Na3VO4, 1 mM DTT, 400 Units/ml DNase I, and 1 Roche protease inhibitor tablet per 25 ml). Extraction was allowed to proceed under agitation for 30 min at 4° C. before the extract was clarified by centrifugation at 13000 g. The extract was diluted 3:1 in buffer D (50 mM Tris-Cl, pH 7.4 (RT), 1.5 mM MgCl2, 25 mM NaF, 1 mM Na3VO4, 0.6% NP40, 1 mM DTT, and Roche protease inhibitors), centrifuged again, and aliquots were snap frozen in liquid nitrogen and stored at −80° C.
Immunopurification (IP-MS)
Anti-BRD4 (A301-985A, Bethyl Labs) antibody (50 μg) was coupled to 100 μl AminoLink resin (Thermo Fisher Scientific). Cell lysate samples (5 mg) were incubated with prewashed immuno resin on a shaker for 2 h at 4° C. Beads were washed in lysis buffer containing 0.4% Igepal-CA630 and lysis buffer without detergent followed by two washing steps with 150 mM NaCl.
Samples were processed by on-bead digest with Lys-C and Glycine protease before they were reduced, alkylated and digested with Trypsin.
NanoLC-MS Analysis
The nano HPLC system used was an UltiMate 3000 HPLC RSLC nano system (Thermo Fisher Scientific, Amsterdam, Netherlands) coupled to a Q Exactive mass spectrometer (Thermo Fisher Scientific, Bremen, Germany), equipped with a Proxeon nanospray source (Thermo Fisher Scientific, Odense, Denmark).
The Q Exactive mass spectrometer was operated in data-dependent mode, using a full scan (m/z range 350-1650, nominal resolution of 70 000, target value 1E6) followed by MS/MS scans of the 12 most abundant ions. MS/MS spectra were acquired using normalized collision energy 30%, isolation width of 2 and the target value was set to 5E4. Precursor ions selected for fragmentation (charge state 2 and higher) were put on a dynamic exclusion list for 30 s. Additionally, the underfill ratio was set to 20% resulting in an intensity threshold of 2E4. The peptide match feature and the exclude isotopes feature were enabled.
Data Analysis
For peptide identification, the RAW-files were loaded into Proteome Discoverer (version 1.4.0.288, Thermo Scientific). All hereby created MS/MS spectra were searched using Mascot 2.2.07 (Matrix Science, London, UK) against the human swissprot protein sequence database. The following search parameters were used: Beta-methylthiolation on cysteine was set as a fixed modification, oxidation on methionine. Monoisotopic masses were searched within unrestricted protein masses for tryptic peptides. The peptide mass tolerance was set to ±5 ppm and the fragment mass tolerance to ±30 mmu. The maximal number of missed cleavages was set to 2. For calculation of protein areas Event Detector node and Precursor Ions Area Detector node, both integrated in Thermo Proteome Discoverer, were used. The result was filtered to 1% FDR using Percolator algorithm integrated in Thermo Proteome Discoverer. Additional data processing of the triplicate runs including label-free quantification was performed in MaxQuant using the Andromeda search engine applying the same search parameters as for Mascot database search. For subsequent statistical analysis Perseus software platform was used to create volcano plots, heat maps and hierarchical clustering.
ChIPmentation
ChIPmentation experiments were performed as described in Schmidl et al., Nature Methods 201517. ChIP-Seq Sample Preparation
Three 15 cm dishes with cells at 70-80% of confluency were used for one ChIP experiment. Briefly, cells were cross-linked with 1% formaldehyde for 10 minutes at room temperature, and then quenched with 125 mM glycine for 5 minutes at room temperature. Then, cells were washed with cold PBS, collected in 15 ml tubes and washed again with cold PBS by centrifugation at 1200 rpm for 5 minutes at 4° C. and finally snap frozen.
ChIP was performed as described18 by using BRD4 (Bethyl Laboratories, Inc.) and MTHFD1 (sc-271413, Santa Cruz) antibodies. In brief, crosslinked cell lysates were sonicated in order to shred the chromatin into 200-500 bp fragments. Fragmented chromatin was incubated overnight at 4° C. with antibodies, followed by 2 hours at 4° C. with pre-blocked Dynabeads Protein G (ThermoFisher Scientific). Beads were washed twice with low salt buffer, twice with high salt buffer, twice with LiCl buffer, twice with 1× TE buffer and finally eluted with elution buffer for 20 min at 65° C. The elution products were treated with RNaseA for 30 minutes at 37° C., followed by proteinase K treatment at 55° C. for 1 hour, and then incubated at 65° C. overnight to reverse the crosslinks. The samples were further purified by using a PCR purification kit (Qiagen). ChIP-seq libraries were sequenced by the Biomedical Sequencing Facility at CeMM using the Illumina HiSeq3000/4000 platform and the 50-bp single-end configuration.
ChIP-Seq Data Analysis
Reads containing adapters were trimmed using Skewer19 and aligned to the hg19/GRCh37 assembly of the Human genome using Bowtie220 with the “—very-sensitive” parameter and duplicate reads were marked and removed with sambamba. Library quality was assessed with the phantomPeakQualtools scripts21. For visualization exclusively, the inventors generated genome browser tracks with the genomeCoverageBed command in BEDTools22 and normalized such that each value represents the read count per base pair per million mapped and filtered reads. This was done for each sample individually and for replicates merged. In visualizations, the inventors simply subtracted the respective merged control IgG tracks from each merged IP using IGV23. They used HOMER findPeaks24 in “factor” mode to call peaks on both replicates with matched IgG controls as background and used DiffBind25 to detect differential binding of BRD4 or MTHFD1 in H3K27ac peaks dependent on dBET6 treatment. The top 500 differential regions for each comparison (sorted by p-value) were used for visualization using SeqPlots26 and clustering with using the concentration values of each factor in each condition estimated with DiffBind. The same top differential regions were input into Enrichr27 as BED files and enrichments for Reactome pathway were retrieved.
Molecular Modeling
For calculating the binding affinity of MTHFD1(K56ac) towards BRD4, six crystal structures of BRD4 co-crystallized with any peptide were downloaded from the RCSB Protein Databank (PDB; www.rcsb.org)28. The X-ray structures were prepared using the QuickPrep protocol of the MOE software package. With that, hydrogens and missing atoms were added, charges were calculated, protonation states optimized and clashes and strain were removed by performing a short energy minimization. Prior to mutating the co-crystallized peptide into the MTHFD1(K56ac), the crucial interaction of the acetylated Lys with Asn140 was restrained. The virtual mutations as well as the affinity and stability calculations were performed using the Protein Design tools (Residue Scan with default settings) of the MOE software package.
For predicting the binding of Methotrexate (MTX) to MTHFD1 (acetylated and unacetylated), the X-ray structure 1A4I was prepared with the QuickPrep protocol of MOE. As the binding pocket of 1A4I is highly solvated, water molecules might interfere with MTX binding during the docking run. Therefore, water molecules were removed for all calculations. For the comparison of binding acetylated vs unacetylated MTHFD1, the prepared crystal structure was acetylated using the Protein Builder in MOE, followed by a short energy minimization of the mutated residue. Furthermore, MTX was prepared and protonated in MOE. A conformational analysis using the LowModeMD method with default settings provided 37 different MTX conformations. These 37 conformations were docked into the acetylated and unacetylated structures of MTHFD1 using the induced fit docking protocol in MOE with default settings.
Interaction fingerprints of the docked structures were calculated using the PLIF tool in MOE.
Chromatin Purification and LC-MS/MS Analysis
Cell fractionation and chromatin enrichment was carried out as previously described29 with some adaptations. Briefly, for 100 million cells, the chromatin enriched pellet was taken up in 250 μl benzonase digestion buffer (15 mM HEPES, 1 mM EDTA, 1 mM EGTA, 0.1% NP40, protease inhibitor cocktail (cOmplete, Roche)) after washing, and sonicated for 120 seconds on the Covaris S220 focused-ultrasonicator with the following settings: Peak Power 140; Duty-Factor 10.0; Cycles/Burst 200. After addition of 0.25 U benzonase and 2.5 μg RNase, the chromatin was incubated for 40 minutes at 4° C. on a rotary shaker. 2× SDS lysis buffer (100 mM HEPES, 4% SDS, 2 mM PMSF and protease inhibitor cocktail (cOmplete, Roche)) was added to the samples in a 1:1 ratio and incubated for 10 minutes at room temperature followed by 5 minutes denaturation at 99° C. After centrifugation at 16,000 g for 10 minutes at room temperature, the supernatant was transferred to a new tube. MS sample preparation was performed using the FASP protocol as previously described30. Reverse-phase chromatography at high and low pH was performed for two-dimensional peptide separation prior to MSMS analysis. Peptides were purified using solid-phase extraction (SPE) (MacroSpin Columns, 30-300 μg capacity, Nest Group Inc. Southboro, Mass., USA) and reconstituted in 23 μL 5% acetonitrile, 10 mM ammonium formate. An Agilent 1200 HPLC system (Agilent Biotechnologies, Palo Alto, Calif.) equipped with a Gemini-NX C18 (150×2 mm, 3 μm, 110 Å, Phenomenex, Torrance, US) column was used for the first dimension of liquid chromatography. Peptides were separated into 20 time based fractions during a 30 min gradient ranging from 5 to 90% acetonitrile containing 10 mM ammonium formate, pH 10, at a flow rate of 100 μL/min. Samples were acidified by the addition of 5 μL 5% formic acid. Solvent was removed in a vacuum concentrator, and samples were reconstituted in 5% formic acid. Mass spectrometric analyses were performed on a Q Exactive mass spectrometer (ThermoFisher, Bremen, Germany) coupled online to an Agilent 1200 series dual pump HPLC system (Agilent Biotechnologies, Palo Alto, Calif.). Samples were transferred from the thermostatted autosampler (4° C.) to a trap column (Zorbax 300SB-C18 5 μm, 5×0.3 mm, Agilent Biotechnologies, Palo Alto, Calif., USA) at a constant flow rate of 45 μL/min. Analyte separation occurred on a 20 cm 75 μm inner diameter analytical column, that was packed with Reprosil C18 (Dr. Maisch, Ammerbuch-Entringen, Germany) in house. The 60-minute gradient ranged from 3% to 40% organic phase at a constant flow rate of 250 nL/min. The mobile phases used for the HPLC were 0.4% formic acid and 90% acetonitrile plus 0.4% formic acid for aqueous and organic phase, respectively. The Q Exactive mass spectrometer was operated in data-dependent mode with up to 10 MSMS scans following each full scan. Previously fragmented ions were dynamically excluded from repeated fragmentation for 20 seconds. 100 ms and 120 ms were allowed as the maximum ion injection time for MS and MSMS scans, respectively. The analyzer resolution was set to 70,000 for MS scans and 35,000 for MSMS scans. The automatic gain control was set to 3×106 and 2×105 for MS and MSMS, respectively, to prevent the overfilling of the C-trap. The underfill ratio for MSMS was set to 6%, which corresponds to an intensity threshold of 1×105 to accept a peptide for fragmentation. Higher collision energy induced dissociation (HCD) at a normalized collision energy (NCE) of 34 was employed for peptide fragmentation and reporter ion generation. The ubiquitous contaminating siloxane ion Si(CH3)2O)6 was used as a single lock mass at m/z 445.120024 for internal mass calibration.
MS Data Analysis (Chromatin Fraction)
The acquired raw MS data files were processed as previously described31. The resultant peak lists were searched against the human SwissProt database version 20150601 with the search engines Mascot (v.2.3.02) and Phenyx (v.2.5.14).
For TMT quantitation the isobar R package was used32. As the first step of the quantitation, the reporter ion intensities were normalized in silico to result in equal median intensity in each TMT reporter channel. Isobar statistical model considers two P-values: P-value sample that compares the abundance changes due to the treatment to the abundance changes seen between biological replicates and P-value ratio that models for noise/variability in mass spectrometry data collection. P-value ratio was further corrected for false discovery rate (FDR). Abundance of a protein was considered to be changed significantly if both P-value sample and FDR corrected P-value ratio were less than 0.05.
Preparation of Nuclear Cell Extracts for Metabolomics
Nuclei were extracted by hypotonic lysis. Briefly, intact cells treated (as indicated in the results section) were washed twice with cold PBS and incubated on ice for 10 minutes with hypotonic lysis buffer (10 mM HEPES, pH 7.9, with 1.5 mM MgCl2, 10 mM KCl and protease inhibitor cocktail (cOmplete, Roche); buffer-cells volume ratio 5:1). Pellet was gently resuspended three times during the incubation. Nuclei were collected by centrifugation (420 g×5 minutes) and immediately snap frozen.
The metabolomic assay and data analysis was performed by Metabolomic Discoveries (http://www.metabolomicdiscoveries.com; Germany). Briefly, LC-QTOF/MS-based non-targeted metabolite profiting was used to analyze nuclear metabolites in the range of 50-1700 Da, with an accuracy up to 1-2 ppm and a resolution of mass/Δmass=40,000. Metabolites measured in the LC are annotated according to their accurate mass and subsequent sum formula prediction. Metabolites that were not annotated in the LC-MS-analyses are listed according to their accurate mass and retention time.
Metabolite Set Enrichment Analysis
Metabolite set enrichment analysis (MSEA)33 was performed using the online tool MetaboAnalyst34 (http://www.metaboanalyst.ca/). Briefly, for each pre-defined functional group a fold-change is computed between the observed number of significantly altered metabolites (considering both up- and down-regulation, t-test with p-value <0.05) and random expectation, as well as a corresponding pvalue (using Fisher's exact test).
Folate Extraction and LC MS/MS Analysis
In order to quantify folates in the nuclear and cytosolic fractions, 20 millions of HAP1 cells per condition were washed twice with cold PBS, and collected into 50 ml falcon tube by centrifugation for 5 minutes at 280 g and 4° C. Cell lysis was performed on ice in the dark by incubating cell pellets with 1:5 hypotonic lysis buffer for 10 minutes. Nuclei were collected by centrifugation for 5 minutes at 420 g and 4° C. Supernatants (cytosolic fractions) were also collected. Both fractions were immediately snap frozen.
For nucleus samples, 10 μL of ISTD mixture was added to nucleus pellet in 1.5 mL Eppendorf tube followed by addition of 145 μL of ice-cold extraction solvent (10 mg/mL ascorbic acid solution in 80% methanol, 20% water, v/v). The samples were vortexed for 10 seconds, afterwards incubated on ice for 3 min and vortexed again for 10 seconds. After centrifugation (14000 rpm, 10 min, 4° C.), the supernatant was collected into HPLC vials. The extraction step was repeated and combined supernatants were used for LC-MS/MS analysis.
For cytoplasm samples, 10 μL of ISTD mixture was added to 75 μL of cytoplasm 1.5 mL Eppendorf tube followed by addition of 215 μL of ice-cold extraction solvent (10 mg/mL ascorbic acid solution in 80% methanol, 20% water, v/v). The samples were vortexed for 10 seconds, afterwards incubated on ice for 3 min and vortexed again for 10 seconds. After centrifugation (14000 rpm, 10 min, 4° C.), the supernatant was collected into HPLC vials and used for LC-MS/MS analysis.
An Acquity UHPLC system (Waters) coupled with Xevo TQ-MS (Waters) triple quadrupole mass spectrometer was used for quantitative analysis of metabolites. The separation was conducted on an ACQUITY HSS 13, 1.8 μm, 2.1×100 mm column (Waters) equipped with an Acquity HSS T3 1.8 μM Vanguard guard column (Waters) at 40° C. The separation was carried out using 0.1% formic acid (v/v) in water as a mobile phase A, and 0.1% formic acid (v/v) in methanol as a mobile phase B. The gradient elution with a flow rate 0.5 mL/min was performed with a total analysis time of 10 min. The autosampler temperature was set to 4° C. For detection, Waters Xevo TQ-MS in positive electrospray ionization mode with multiple reaction mode was employed. Quantification of all metabolites was performed using MassLynx V4.1 software from Waters. The seven-point linear calibration curves with internal standardization and 1/× weighing was constructed for the quantification.
Mouse Xenograft Studies
Mouse xenograft studies were performed as described previously35. 2×106 A549 cells, diluted 1:1 in matrigel, were transplanted subcutaneously into NOD SCID gamma mice. Treatment (30 mg/kg (S)-JQ1 by intraperitoneal injection five times per week, and 25 mg/kg MTX per intraperitoneal injection twice weekly) was started when tumors were established, 19 days post transplantation. Tumor volumes were evaluated twice a week by measuring two perpendicular diameters with calipers. Tumor volume was calculated using the following equation: (width*width*length)/2. Treatment was performed according to an animal licence protocol approved by the Bundesministerium für Wissenschaft and Forschung (BMWF-66.009/0280-II/3b/2012). At day 43 mice were sacrificed and tumors excised and weighted.
A Genetic Loss-of-Function Screen for BRD4 Pathway Genes
The prerequisite for effective GT genetic screens is a haploid system where monoallelic disruptive GT integration results in gene knock-out (KO). Therefore, KBM7 cells, a chronic myeloid leukemia cell line with near haploid karyotype, were chosen for the generation of the BRD4 reporter cell lines as previously described15. The inhibition of BRD4 with the potent inhibitor (S)-JQ1 led to rapid and consistent expression of the reporter gene red fluorescent protein (RFP) in REDS, which could easily be detected by FACS (see
The suitability of the REDS1 clone for a GT-based genetic screen was then further validated. The clone harbors a single genomic RFP integration as determined by fluorescence in situ hybridization (see
With the REDS1 clone validated, a GT-mediated genetic screen was performed in order to identify new functional partners for BRD4 (see
MTHFD1 is Recruited to Chromatin by Physical Interaction with BRD4
To understand the role of MTHFD1 in BRD4-mediated gene regulation, it was tested whether these two proteins interacted physically. Therefore, HEK293T cells were transfected with a plasmid encoding for GFP-MTHFD1. After 48 hours, GFP pull-down (PD) was performed and showed that BRD4 could co-immunoprecipitate (co-IP) with overexpressed (OE) MTHFD1 (see
While BRD4 is localized almost exclusively to the nucleus, the folate biosynthesis is considered to occur in the cytoplasm and mitochondria. However, recently SUMOylation dependent nuclear import of folate pathway enzymes has been described36-39. Nuclear vs cytosolic fractionation of HAP1, KBM7 and HEK293T cells indicated that MTHFD1 can be detected in the nucleus in all three cell lines (see
MTHFD1 Occupies Defined Genomic Loci at a Subset of BRD4 Binding Sites
Having characterized BRD4-dependent chromatin recruitment of MTHFD1, the inventors wanted to map the genomic binding sites of the folate pathway enzyme. Therefore, ChIPmentation experiments17 were performed in HAP1 cells. MTHFD1 was found to bind to distinct genomic loci and in total 242 MTHFD1 peaks along the genome were observed. The overlap between MTHFD1 binding sites and BRD4 loci was analyzed next. In line with the proteomic experiments, the vast majority of MTHFD1 binding sites overlapped with BRD4 binding sites. MTHFD1 binding sites are predominantly found in proximity of BRD4 peaks (see
MTHFD1 and BRD4 Control Nuclear Metabolite Composition
MTHFD1 is a C-1-tetrahydrofolate synthase that catalyzes three enzymatic reactions in folate metabolism, resulting in the interconversion of tetrahydrofolate (THF), 10-formyltetrahydrofolate (10-CHO-THF), 5,10-methenyltetrahydrofolate (5,10-CH=THF) and 5,10-methylenetetrahydrofolate (5,10-CH2-THF). These folates are key intermediates of one carbon metabolism and provide activated C1 groups for the biosynthesis of purines, pyrimidines and methionine. All three classes of C1 metabolism products have the potential to contribute to transcriptional control. Pyrimidines and purines are incorporated into nucleobases, which in turn are converted in the nucleotides, which are the substrates for the replicative and transcriptional machinery. Methionine metabolism results in the generation of S-Adenosyl-Methionine (SAM), the methyldonor for all histone and DNA-methyltransferases. Biosynthesis of the three major classes of C1 metabolism products, purines, pyrimidines and methionine, is considered to occur in the cytoplasm and mitochondria of mammalian cells. To test whether the entire biosynthetic pathway occurs in the nucleus, the chromatin-associated protein fraction was analyzed for metabolic enzymes. Both thymidylate synthase and several enzymes of the purine biosynthesis pathways (GART, PAICS, ATIC) were found bound to chromatin in HAP1 cells (see
BRD4 Inhibitors Synergize with Anti-Folates in Diverse Cancer Cell Lines
Based on the similarities in nuclear metabolite composition following loss of MTHFD1 and BRD4, it was speculated that antifolates might synergize with BRD4 inhibitors in cancer cells. To test this hypothesis, a panel of six cell lines were selected, including four cell lines described to be not sensitive to BRD4 inhibition, plus KBM7 and HAP1 which were routinely used for the experiments (see
| Number | Date | Country | Kind |
|---|---|---|---|
| 16198760.7 | Nov 2016 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2017/079225 | 11/14/2017 | WO | 00 |
